News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Cynvenio Biosystems, Inc. Announces New Data Describing Superior Utility Of Sequenced DNA From LiquidBiopsy® Tumor Cells vs Cell Free DNA To Be Presented At The American Association for Cancer Research 2014 Meeting


4/4/2014 9:06:32 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

AACR Annual Meeting, April 5-9, 2014 – Cynvenio Biosystems, Inc., a molecular diagnostics company focused on transforming targeted cancer treatment, will present data that sequence analysis of DNA recovered from circulating tumor cells (CTCdna) outperforms cell free derived DNA (cfDNA) template from the same patient sample at the American Association for Cancer Research (AACR) Annual Meeting on April 7 in San Diego, Calif. The performance differences were noted in the significantly better detection of clinically relevant mutations from Cynvenio’s CTCdna obtained by LiquidBiopsy.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES